ARCHIVES

FDA Should Delay Provenge Decision Pending Definitive Trial Results, ODAC Chairman Writes.

This article is from The Cancer Letter archive.

Vol. 33 No. 16 | April 27, 2007

Download PDF Visit The Full Archive

Related Articles

NLST Shows 20.3 Percent Mortality Benefit For CT Vs. X-Ray In Lung Cancer Screening

November 5, 2010

Six Institutions Get Awards For LAK-IL-2 Trials

February 7, 1986

In Brief: UC Irvine Wins Grant For Trial Of One-Visit Cervical Cancer Screening, Treatment

November 6, 1998

Patients Sue Milken, Cancer Centers, Over Prostate Cancer Remedy PC-Spes

February 20, 2004

Survivorship Studies Unfocused As Total Research Increases

November 25, 2011

Mayo’s Regional Program – Keys To Success Are Service, Communications

December 9, 1977